Valeo Financial Advisors LLC Acquires Shares of Bio-Techne Co. (NASDAQ:TECH)

Financial Advisors

Valeo Financial Advisors LLC recently announced that it has secured a new stake in Biotechne, Inc. (NASDAQ:TECH) through its latest 13F filing with the Securities and Exchange Commission. The investment firm said it had acquired approximately 3,083 shares of the biotechnology company, worth approximately $256,000.

Bio-Techne is a renowned biotechnology company engaged in the research and development of diagnostic and therapeutic agents for use in clinical laboratories worldwide. The company’s research areas are primarily focused on cytokines and growth factors, immunoassays, antibodies and a number of combined tissue and culture reagents and small molecules. With its portfolio spanning the fields of neuroscience, stem cell, and cancer biology, just to name a few, it’s no wonder outside investors are interested in acquiring a portion of its stake.

In its recently released quarterly report filed on May 3, Biotechne beat estimates at $0.53 per share and $0.05 above consensus expectations of $0.48 per share, respectively. Investor interest in biopharmaceutical company stocks is growing.

In fact, a closer look at this year’s financial results reveals that globally, as evidenced by last quarter earnings of more than $294 million versus an estimated $298 million. We can see that Bio-Techne maintains a stable performance even during these difficult times. This has been proven again. The company is one of the few powerhouses in the industry that can move forward.

Their commitment to protein science research and diagnostics is supported by talented team players. As we all are determined to find solutions to chronic diseases like cancer and Alzheimer’s, we are all working toward long-term goals with ambitious goals and strategies never seen before. , convincing stakeholders that the return on investment will fall (or rise) sooner than ever before. A line that yields profit over time. Moreover, this is an industry relevance, as companies like Biotechne are steadily gaining ground in the field, steadily glimpsing what pharmaceutical investments can bring to the future of healthcare. Good news for those



Updated: 2023/05/17

financial soundness


D/E ratio: Neutral

Price Earnings: Strong Buy

Price to Book: Strong Buy

show more

target price

the current $81.94

consensus $101.92

low $89.00

Median $100.00

expensive $125.00

show more

social emotion

No social sentiment data found for this stock

Analyst Rating

Analyst/Corporate evaluation
Deutsche Bank buy
city ​​group buy
RBC Capital buy
stevens buy

Paul Knight
key bank

wells fargo buy

show more

Institutional investors increase stakes in Biotechne despite stable share price

A number of institutional investors and hedge funds are trading in Biotechne’s shares, according to recent reports. In particular, Vanguard Group increased its stake in the biotech company by 0.6% to 4,487,742 shares worth $1,274.52 million after acquiring an additional 27,397 shares during the most recent trading period. BlackRock Inc also increased his Bio-Techne stake by 0.9% in Q3, and Ownership Capital BV increased its stake by a whopping 338.8% in Q4. Spring Global Investments Holdings is another investor that recently increased its stake in Biotechne.

Despite the move, NASDAQ:TECH stock on Tuesday opened at $81.08 for Biotechne, which is valued at $12.76 billion.

Bio-Techne develops and markets biotechnology reagents and instruments for the research and clinical diagnostic markets through its two divisions, Protein Science and Diagnostics & Genomics. The company’s protein science division focuses on immunoassays for cytokine and growth factor antibodies, as well as other biologically active small molecule compounds.

Bio-Techne recently announced its quarterly dividend on Friday, May 26th. Shareholders of record on Monday, May 15 will receive a dividend of $0.08 per share. This equates to an annualized dividend of $0.32 with an ex-dividend date set for Friday, May 12th.

Several brokerage firms have commented on TECH in recent months. KeyCorp lowered its price target to $115 from $125, but Robert W. Baird said his company’s price target for the stock trading period was just under $80 over the 200-day trading period, based on moving average data that was just under $80. We have raised our forecast to $100 from $99. history.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *